Is Donanemab a Breakthrough Treatment for Alzheimer’s?
Donanemab, developed by Eli Lilly, is an experimental antibody treatment targeting N3pG amyloid to slow cognitive decline in Alzheimer’s patients. Recently, an FDA advisory group unanimously approved it, highlighting its potential benefits despite risks like brain swelling and bleeding. The drug’s unique trial design and comparison to Leqembi show different safety and efficacy results. The FDA’s final decision, influenced by the panel’s approval, could impact future treatment cycles and management.
If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.
